Journal: Molecular Therapy Oncology

Article Title: Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy

doi: 10.1016/j.omton.2025.201109

Figure Lengend Snippet: MV-s-NAP-uPA + aPD-1 + aTIGIT + paroxetine combination increases S1P1 expression on BM lymphocytes in an orthotopic CT-2A/C57BL/6 mouse model (A) Schematic illustration of the treatment plan. (B) Median S1P1 staining in the BM lymphocytes 8 days post-CT-2A implantation. (C) Median S1P1 staining in the BM lymphocytes 13/14 days post-CT-2A implantation. (D) Median S1P1 staining in the CD4+ BM lymphocytes 13/14 days post-CT-2A implantation. (E) Median S1P1 staining in the CD8+ BM lymphocytes 13/14 days post-CT-2A implantation. (F) Median S1P1 staining in the NKT BM lymphocytes 13/14 days post-CT-2A implantation. The graphs represent the mean values obtained with flow cytometry analysis of the isolated tissue. Statistical analysis was conducted with a one-way ANOVA followed by Tukey’s multiple comparisons test, with 3–4 mice analyzed per group at each time point. p values less than 0.05 were considered significant.

Article Snippet: The antibodies used were the following: aPD-1 (anti-mPD-1-mIgG1e3, clone: RMP1-14, rat IgG2a,κ and features mouse IgG1e3 isotype-constant region; InvivoGen, San Diego, CA, CAT #mpd1-mab15-10) and aTIGIT (anti-mTIGIT-mIgG2a, clone: 10A7, hamster IgG2a and features the mIgG2a isotype-constant region; InvivoGen, San Diego, CA, CAT #mtigit-mab10-10).

Techniques: Expressing, Staining, Flow Cytometry, Isolation

Journal: Molecular Therapy Oncology

Article Title: Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy

doi: 10.1016/j.omton.2025.201109

Figure Lengend Snippet: Paroxetine mobilizes lymphocytes following treatment with MV-s-NAP-uPA oncolytic virotherapy and immunovirotherapy in an orthotopic CT-2A/C57BL/6 mouse model (A) Schematic illustration of the treatment plan. (B) Percentage of circulating lymphocytes among all immune cells in PBMCs on days 13 and 18 post-CT-2A implantation. (C) Standardized counts of CD4+ and CD8+ single-positive PBMCs following MV-s-NAP-uPA + aPD-1 + aTIGIT immunovirotherapy with and without paroxetine on day 13/14 post-CT-2A implantation. (D) Standardized counts of CD4+ and CD8+ single-positive PBMCs following MV-s-NAP-uPA oncolytic virotherapy with and without paroxetine on day 13/14 post-CT-2A implantation. (E) Comparison of thymus weights in mice reaching a predetermined sacrifice endpoint, evaluating the effects of paroxetine vs. respective controls. For (B–D), the graphs represent the mean values obtained with flow cytometry analysis of the isolated tissue. Statistical analysis was conducted with one-way ANOVA followed by Tukey’s multiple comparisons test, with 3–4 mice analyzed per group at each time point for (B–D) and 11–26 mice analyzed per group for (E). p values less than 0.05 were considered significant.

Article Snippet: The antibodies used were the following: aPD-1 (anti-mPD-1-mIgG1e3, clone: RMP1-14, rat IgG2a,κ and features mouse IgG1e3 isotype-constant region; InvivoGen, San Diego, CA, CAT #mpd1-mab15-10) and aTIGIT (anti-mTIGIT-mIgG2a, clone: 10A7, hamster IgG2a and features the mIgG2a isotype-constant region; InvivoGen, San Diego, CA, CAT #mtigit-mab10-10).

Techniques: Comparison, Flow Cytometry, Isolation

Journal: Molecular Therapy Oncology

Article Title: Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy

doi: 10.1016/j.omton.2025.201109

Figure Lengend Snippet: Paroxetine enhances lymphocyte activation in lymphoid organs and peripheral blood following treatment with MV-s-NAP-uPA + aPD-1 + aTIGIT immunovirotherapy in an orthotopic CT-2A/C57BL/6 mouse model (A) Schematic illustration of the treatment plan. (B) Percentage of CD69+ double-positive (CD4+CD8+) and single-positive helper T cells (CD4+) in the thymus of mice treated with immunovirotherapy with and without paroxetine on day 8 post-CT-2A implantation. (C–E) Percentage of CD25+/FOXP3− CD4+ cells in the thymus, spleen, and BM of mice treated with immunovirotherapy with and without paroxetine on day 8 post-CT-2A implantation. (F) Percentage of CD25+/FOXP3− CD8+ cells in the peripheral blood of mice treated with immunovirotherapy with and without paroxetine on days 8 and 13 post-CT-2A implantation. (G) Percentage of Tregs in the BM of mice treated with immunovirotherapy with and without paroxetine on day 18 post-CT-2A implantation. (H) Percentage of TIM-3+ lymphocytes in the thymus on day 18 post-CT-2A implantation. (I) Percentage of PD-1+ CD8+ cells in the spleen on day 18 post-CT-2A implantation. The graphs represent the mean values obtained with flow cytometry analysis of the isolated tissues. Statistical analysis was conducted with student two-tailed t tests with 3–4 mice analyzed per group at each time point. p values less than 0.05 were considered significant.

Article Snippet: The antibodies used were the following: aPD-1 (anti-mPD-1-mIgG1e3, clone: RMP1-14, rat IgG2a,κ and features mouse IgG1e3 isotype-constant region; InvivoGen, San Diego, CA, CAT #mpd1-mab15-10) and aTIGIT (anti-mTIGIT-mIgG2a, clone: 10A7, hamster IgG2a and features the mIgG2a isotype-constant region; InvivoGen, San Diego, CA, CAT #mtigit-mab10-10).

Techniques: Activation Assay, Flow Cytometry, Isolation, Two Tailed Test

Journal: Molecular Therapy Oncology

Article Title: Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy

doi: 10.1016/j.omton.2025.201109

Figure Lengend Snippet: The effect of paroxetine on the survival in an orthotopic CT-2A/C57BL/6 mouse model treated with MV-s-NAP-uPA + aPD-1 + aTIGIT immunovirotherapy (A) Schematic illustration of the treatment plan in the pilot survival mouse experiment. (B) Kaplan-Meier plot representing the survival in the pilot study evaluating the effect of paroxetine and/or G-CSF in combination with immunovirotherapy (n = 4–8 mice per group). (C) Schematic illustration of our rechallenge experiment. (D) Kaplan-Meier plot representing the survival following rechallenge of the surviving mice from each group 180 days after the original tumor implantation with the same CT-2A cell line or a foreign melanoma B16-F10 cell line (n = 3–4 mice per group). Mice were rechallenged with intracranial implantation. (E) Schematic illustration of the treatment plan for the survival experiment presented in F. (F) Kaplan-Meier plot representing the survival following treatment with paroxetine in combination with oncolytic virotherapy, immunotherapy, and immunovirotherapy (n = 6–17 mice per group). p values less than 0.05 were considered significant.

Article Snippet: The antibodies used were the following: aPD-1 (anti-mPD-1-mIgG1e3, clone: RMP1-14, rat IgG2a,κ and features mouse IgG1e3 isotype-constant region; InvivoGen, San Diego, CA, CAT #mpd1-mab15-10) and aTIGIT (anti-mTIGIT-mIgG2a, clone: 10A7, hamster IgG2a and features the mIgG2a isotype-constant region; InvivoGen, San Diego, CA, CAT #mtigit-mab10-10).

Techniques: Tumor Implantation

Journal: Molecular Therapy Oncology

Article Title: Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy

doi: 10.1016/j.omton.2025.201109

Figure Lengend Snippet: Combination therapy with MV-s-NAP-uPA + aPD-1 + aTIGIT + paroxetine does not increase toxicity in the orthotopic CT-2A/C57BL/6 mouse model (A) Mice from the survival studies were weighed every 3–4 days, and the percent change from baseline is presented longitudinally. Except for a brief post-operative weight loss, which was consistent across vehicle-treated mice and those receiving combinations based on MV-s-NAP-uPA, all treated mice, regardless of their treatment groups, gained weight at a comparable rate. (B) Cytokine analysis for IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IFN-γ, IL-12p70, GM-CSF, TNF-α, and IL-18 was performed on plasma samples collected from mice on days 8, 13/14, and 18/19 post-CT-2A implantation. The graphs in (B) represent the mean values obtained from 3–4 mice per group at each time point.

Article Snippet: The antibodies used were the following: aPD-1 (anti-mPD-1-mIgG1e3, clone: RMP1-14, rat IgG2a,κ and features mouse IgG1e3 isotype-constant region; InvivoGen, San Diego, CA, CAT #mpd1-mab15-10) and aTIGIT (anti-mTIGIT-mIgG2a, clone: 10A7, hamster IgG2a and features the mIgG2a isotype-constant region; InvivoGen, San Diego, CA, CAT #mtigit-mab10-10).

Techniques: Clinical Proteomics

Journal: Cyborg and Bionic Systems

Article Title: Nano-Immunotherapy Synergizing Ferroptosis and STING Activation in Metastatic Bladder Cancer

doi: 10.34133/cbsystems.0458

Figure Lengend Snippet: Preparation and characterization of MPP@IKE-aPD-1/diABZI. (A) Schematic diagram of MPP@IKE-aPD-1/diABZI preparation. (B) Particle size of nanomedicine. (C) TEM images of MPP@IKE-aPD-1/diABZI nanomedicine incubated in different environments. Scale bar, 50 nm. (D) Cumulative release of diABZI-C2-NH2 comes from pH 7.4 and pH 6.5. (E) Accumulated release of aPD-1 in pH 7.4, pH 6.5, and pH 6.5 + 10 mM GSH environments.

Article Snippet: The ferroptosis inducer IKE (imidazole ketone erastin), STING agonist diABZI, and anti-PD-1 antibody (aPD-1) were obtained from MedChemExpress.

Techniques: Incubation